Profile
Cleland C.
Landolt served as the Medical Director at Singulex, Inc. He was the Vice President-Business Development at Collateral Therapeutics, Inc. from 2001 to 2007.
He also served as the Chief Medical Officer at Berkeley HeartLab, Inc. Dr. Landolt received his undergraduate degree from Harvard University in 1971 and his doctorate degree from Cornell University in 1975.
Former positions of Cleland C. Landolt
Companies | Position | End |
---|---|---|
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Corporate Officer/Principal | 10/10/2007 |
Singulex, Inc.
Singulex, Inc. Miscellaneous Commercial ServicesCommercial Services Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA. | Chief Tech/Sci/R&D Officer | - |
Berkeley HeartLab, Inc.
Berkeley HeartLab, Inc. Medical/Nursing ServicesHealth Services Berkeley HeartLab Inc. operates as a cardiovascular healthcare company. It provides cardiovascular disease management tools and services, with focus on the secondary prevention market. The company was founded by Robert H. Superko in 1995 and is headquartered in CA. | Chief Tech/Sci/R&D Officer | - |
Training of Cleland C. Landolt
Cornell University | Doctorate Degree |
Harvard University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Commercial Services |
Berkeley HeartLab, Inc.
Berkeley HeartLab, Inc. Medical/Nursing ServicesHealth Services Berkeley HeartLab Inc. operates as a cardiovascular healthcare company. It provides cardiovascular disease management tools and services, with focus on the secondary prevention market. The company was founded by Robert H. Superko in 1995 and is headquartered in CA. | Health Services |
Singulex, Inc.
Singulex, Inc. Miscellaneous Commercial ServicesCommercial Services Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA. | Commercial Services |
- Stock Market
- Insiders
- Cleland C. Landolt